Conference Agenda

7th Annual BFC HealthCare Business Development & Investment Conference 2021

Oct. 12~14, 2021 -- JW Marriott Hotel Shanghai at Tomorrow Square

  • TIME
    ACTIVITIES           Tuesday, Oct. 12, 2021
  • 13:00 – 13:30
    BFC Introduction 1 - Cross-border Licensing Trends

    Moderator:Shirley Lu, VP, BFC Group
  • 13:30 – 14:30
    Rising deal opportunities in the biospecific and ADC areas

    Moderator:Ying Yang, Vice President, Worldwide Business Development Asia Lead, Pfizer
    David Poon, Vice President, Business Development & Alliance Management, Zymeworks
    Per Hellsund,CEO,Cybrexa
    Pengfei Zhou, CEO, Wuhan YZY Biopharma
    Liang Wu, China Business Development Lead, BMS
    Angelika Bonin-Debs, Corporate Director Licensing, Boehringer Ingelheim GmbH
    Patrick A. Baeuerle, CSO, Cullinan Oncology
  • 14:30 – 15:30
    New modality, new deal opportunities—deal trend for the next three to five years

    Moderator:Christina Zhang, Managing Partner, Shanghai Office, Cooley
    Guillaume Vignon, Senior Vice President Business Development at BeiGene
    Matthias Kromayer, General Partner, MIG AG
    Bosun Hau, Managing Director, Co-Head Private Investments, Tybourne Capital
    Jun Song, Head (Executive Director) NIBR BD&L, Region China, Norvatis
    Terry Chen, Head of Business Development, Amgen
    Andrew Wong, Vice President, Transactions & Early Innovation Partnering, Johnson & Johnson Innovation Asia Pacific
  • 15:30 – 16:00
    Tea Break
  • 16:00 – 17:00
    Cell Therapy and Gene Therapy Cross Border Cooperations—Opportunities and challenges

    Moderator:Jin Wan, Executive General Manager, SDIC
    Lei Yu, CEO, Unicar-therapy
    Xiancheng Zhong, co-Founder, Chairman & CEO, Chinagene Tech
    Tongcun Zhang, Chairman and Managing Director , Bio-raid
    Zhongchao Han, Center Director, National Stem Cell Engineering Research Center
    Lixin Jiang,Founder & CEO,Next Generation Gene Therapeutics
  • 17:00 – 17:45
    Hong Kong IPO trends, new policy of Beijing Exchange and the impact of BD transaction

    Moderator:Marco Li,BFC Group
    JessicaLi, Managing Director, Asia Pacific Investment Banking, Bank of America
    Yiming Liu, Partner, Cooley Shanghai
    Shijiang Wang, Sponsor Representative, Sinolink Securities
    Haoran Gong, Executive Director, CMB International Capital Investment Banking Department
    Mark Tang, Managing Director and Founding Partner, Good Health Capital
  • TIME
    ACTIVITIES         Wednesday, Oct. 13, 2021    Panel Discussion & Road Show
  • 8:30 – 9:00
  • 9:00-9:30
    BFC Introduction 2 - Review of China Healthcare Investment in Last 18 Months

    Moderator: David Chen, Managing Director, BFC Group
  • 9:30-10:45
    Panel Discussion 1 – Biotech Investment in the next 10 years

    Moderator: Benjamin Qiu, Partner, Advantech Capital
    Zhihua Yu, Founding Partner, Lapam Capital
    Steven Wang, Partner, OrbiMed Asia
    Jun Wu, Chairman & Managing Partner,Cenova Ventures
    Kevin Chen, Founding Partner, BioTrack Capital
    Leo Shi, Managing Director, Warburg Pincus
    Michael Xue, Managing Director of Morningside Venture
  • 10:45-12:00
    Panel Discussion 2 – The oppotuniteis and challenging of listing the biotech companies in STAR board in the next five years

    Moderator:Wei Song, Business director,Sionlink Securities
    Wen Chen, Partner, Yonghua Capital
    Jinglei Li, Managing Director, Sionlink Securities
    Jin Li, CEO, Hitgen
    Houshun Chang, Managing Director, Sionlink Securities
  • 12:00-13:00
  • 13:00-18:00
    Company Road show
  • TIME
    ACTIVITIES         Thursday, Oct. 14, 2021    Panel Discussion & Road Show
  • 9:20-10:00
    Panel Discussion 3 – Healthcare Deal Momentum —— M&A and IPOs in 2021 and Opportunities in 2022

    Moderator:Toto Ku, Head of Greater China, Datasite
    David Chen, Managing Director, BFC Group
    Yi Yang, Executive Director, Legend Capital
    Jianhua Cai, Vice President, Vivabiotech
    Cherry Yi, Managing Director, GL Capital
    Xiaolan Yang, Vice President& Director& Partner, Genext
  • 10:00-12:00
    Company Road show
  • 12:00-13:00
  • 13:00-13:40
    Panel Discussion 4 – New modality of Immuno oncology field in Post- PD-(L)1 era

    Moderator:Fei Jiang, Managing Director, Hongtai Aplus
    Yi Zhou, General Manager of Healthcare Fund, Shenzhen Capital Group Company
    Hong Ling,CTO, Lead Biolabs
    Jiajian Liu, Founder & CEO, L&L Biopharma
    Jack Han,Founder & CEO,Linno Pharmaceutics
  • 13:40-14:20
    Panel Discussion 5 – Future development for small molecure drugs

    Moderator:Zhuxi Chen, Vice President, SDIC
    Chenchen, Founder, President/CEO , ABM Therapeutics
    Xin Huang, Founder, Hongyun Biotech
    James Fang, CFO, KBP Bioscience
    Tony Zhang, Founder and CEO, Tyligand
    Issac Liu, CEO, Arthur Group
  • 14:20-15:00
    Panel Discussion 6– Trends in diagnostic services

    Moderator:Yinghua Zhou, Founding Managing Partner, Hanne Capital
    Sijia Lu, CEO, Yikon Genomics
    Gang Liu, Chairman&Chief Scientist,Liangzhun
    Qiang Shen, Partner, WisdoMont Asset Management
    Haichuan Zhang, Chairman&CEO, Celula
  • 15:00-15:40
    Panel Discussion 7 – New modality of innovative drugs

    Moderator:Jieyu Zou, Managing Director, Lilly Asia Ventures
    Weiwen Ying, CEO, Ranok Therapeutics
    Lunan Zhang, Managing Director, Advaccine
    Hong Wen, Partner, SIIC
    Dafeng Zhang, Founding Partner, Tao Capital
  • 15:40-16:20
    Panel Discussion 8 – Trends of CNS drug development

    Moderator:Daniel Ying, Director, OrbiMed
    Zhihong Lu, CMO, Bioshin
    Jing Zhang, R&D director
    Huidong Tang, Head of Neurology Department in Ruijin Hospital
    Gongzheng Chen, Vice General Manager, Credit

  • 16:20-17:00
    Panel Discussion 9 – Breakthrough of innovative medical devices

    Moderator:Ting Xiao, Partner, Delos Capitalbr/> Panelists:
    Jianguo Sun, Chairman, Curatia
    Ning Xue, Managing Director, Hengxu Capital
    Lu Jin, Vice Chairman & Non-executive Director, HTDK
    Dezhi Jiao, Strategic Investment Director, Micro-Tech Endoscopy